| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Kimio Tohyama, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Haruhide Kimur. The Journal of pharmacology and experimental therapeutics. 2023-03-31. PMID:37001988. |
loss of orexin neurons is associated with narcolepsy type 1 (nt1), which is characterized by multiple symptoms including excessive daytime sleepiness and cataplexy. |
2023-03-31 |
2023-08-14 |
mouse |
| Yves Dauvilliers, Michel Lecendreux, Gert Jan Lammers, Patricia Franco, Mikhail Poluektov, Christian Caussé, Isabelle Lecomte, Jeanne Marie Lecomte, Philippe Lehert, Jean Charles Schwartz, Giuseppe Plazz. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. The Lancet. Neurology. vol 22. issue 4. 2023-03-17. PMID:36931805. |
pitolisant, a selective histamine h3 receptor inverse agonist, has been approved in europe and usa for adults with narcolepsy with or without cataplexy, with a favourable safety profile. |
2023-03-17 |
2023-08-14 |
Not clear |
| Annika Triller, Fabio Pizza, Michel Lecendreux, Lea Lieberich, Rana Rezaei, Anna Pech de Laclause, Stefano Vandi, Giuseppe Plazzi, Ulf Kallwei. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study. Sleep medicine. vol 103. 2023-02-09. PMID:36758348. |
pitolisant is an inverse histamine 3 receptor agonist and has been approved for the treatment of adult narcolepsy with or without cataplexy by ema and fda. |
2023-02-09 |
2023-08-14 |
Not clear |
| Jean-Baptiste Brunet de Courssou, Pauline Testard, Magali Sallansonnet-Froment, Marie-Laure Brechemier, Damien Ricard, Dimitri Psimaras, Mickaël Ferrand, Thibault Maillet, Patricia Depierre, Charlotte Ohlmann, Jean Capron, Isabelle Arnulf, Ana Gale. Narcolepsy secondary to anti-Ma2 encephalitis: two case reports. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2023-01-28. PMID:36708258. |
patient 1, a 68-year-old man, had narcolepsy type 1 including sleep attacks, cataplexy, abnormal multiple sleep latency tests (mslt) and hypocretin-1 deficiency (<50ng/l) in the cerebrospinal fluid (csf), associated with a cerebellar syndrome. |
2023-01-28 |
2023-08-14 |
Not clear |
| R Peraita-Adrados, J M Bellón, L Lillo-Triguero, P López-Esteban, P Medrano-Martíne. Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1. Revista de neurologia. vol 76. issue 2. 2023-01-12. PMID:36631962. |
sodium oxybate (sxb) was administered for the first time in 1979 in 16 patients with narcolepsy with cataplexy (nt1) that improved up to 20 months. |
2023-01-12 |
2023-08-14 |
Not clear |
| Mayuko Yoshida, Koki Yamamoto, Tomoyuki Kuwak. Positive memory increases cataplexy-like behaviors in narcolepsy mice as revealed using conditioned place preference test. BMC neuroscience. vol 23. issue 1. 2022-12-28. PMID:36577939. |
cataplexy is a loss of muscle tone that can lead to postural collapse, disturbing the daily life of narcolepsy patients; it is often triggered by positive emotions such as laughter in human patients. |
2022-12-28 |
2023-08-14 |
mouse |
| João H C Campos, Ana C R Aguilar, Fernando Antoneli, Giselle Truzzi, Marcelo R S Briones, Renata C Ferreira, Fernando M S Coelh. Whole-genome analysis of monozygotic Brazilian twins discordant for type 1 narcolepsy: a case report. BMC neurology. vol 22. issue 1. 2022-11-19. PMID:36401198. |
narcolepsy type 1 (nt1) is a rare and chronic neurological disease characterized by sudden sleep attacks, overwhelming daytime drowsiness, and cataplexy. |
2022-11-19 |
2023-08-14 |
Not clear |
| Sofia M Buonocore, Robbert G van der Mos. Narcolepsy and H1N1 influenza immunology a decade later: What have we learned? Frontiers in immunology. vol 13. 2022-10-31. PMID:36311717. |
narcolepsy with cataplexy (defined as type-1 narcolepsy, nt1) is characterized by an irreversible and chronic deficiency of hypocretin peptides in the hypothalamus. |
2022-10-31 |
2023-08-14 |
Not clear |
| Valerio Brunetti, Jessica Marotta, Giorgia Simoncini Malucelli, Giuseppe Marano, Marianna Mazza, Giacomo Della Marc. Dissociative episode and panic attacks triggered by pitolisant in a narcoleptic patient. International clinical psychopharmacology. 2022-09-27. PMID:36165509. |
pitolisant is a histamine 3-receptor antagonist/inverse agonist effective and safe for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy. |
2022-09-27 |
2023-08-14 |
Not clear |
| Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Haruhide Kimur. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. Pharmacology, biochemistry, and behavior. 2022-09-15. PMID:36108771. |
narcolepsy type 1 (nt1), caused by loss of orexin neurons, is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, hypnagogic/hypnopompic hallucinations and sleep paralysis, as well as a high risk of obesity. |
2022-09-15 |
2023-08-14 |
mouse |
| Noeen Sarfraz, David Okuampa, Hannah Hansen, Mark Alvarez, Elyse M Cornett, Juyeon Kakazu, Adam M Kaye, Alan D Kay. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health psychology research. vol 10. issue 3. 2022-07-01. PMID:35774905. |
narcolepsy is a debilitating sleep disorder that presents with excessive daytime sleepiness (eds) and cataplexy, which is a sudden paralysis of muscle tone triggered by strong emotions such as laughing. |
2022-07-01 |
2023-08-14 |
Not clear |
| Zhongxing Zhang, Yves Dauvilliers, Giuseppe Plazzi, Geert Mayer, Gert Jan Lammers, Joan Santamaria, Markku Partinen, Sebastiaan Overeem, Rafael Del Rio Villegas, Karel Sonka, Rosa Peraita-Adrados, Raphaël Heinzer, Aleksandra Wierzbicka, Birgit Högl, Mauro Manconi, Eva Feketeova, Antonio Martins da Silva, Jitka Bušková, Claudio L A Bassetti, Lucie Barateau, Fabio Pizza, Elena Antelmi, Jari K Gool, Rolf Fronczek, Carles Gaig, Ramin Khatam. Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. Nature and science of sleep. vol 14. 2022-06-07. PMID:35669411. |
narcolepsy type-1 (nt1) is a rare chronic neurological sleep disorder with excessive daytime sleepiness (eds) as usual first and cataplexy as pathognomonic symptom. |
2022-06-07 |
2023-08-14 |
Not clear |
| Raphaël Bernard-Valnet, David Frieser, Xuan-Hung Nguyen, Leila Khajavi, Clémence Quériault, Sébastien Arthaud, Silvia Melzi, Maxime Fusade-Boyer, Frederick Masson, Matthias Zytnicki, Abdelhadi Saoudi, Yves Dauvilliers, Christelle Peyron, Jan Bauer, Roland S Libla. Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. Brain : a journal of neurology. 2022-05-13. PMID:35552381. |
narcolepsy with cataplexy or narcolepsy type 1 is a disabling chronic sleep disorder resulting from the destruction of orexinergic neurons in the hypothalamus. |
2022-05-13 |
2023-08-13 |
mouse |
| Adrienne Elisabeth van der Hoeven, Rolf Fronczek, Mink Sebastian Schinkelshoek, Frederik Willem Cornelis Roelandse, Jaap Adriaan Bakker, Sebastiaan Overeem, Denise Bijlenga, Gert Jan Lammer. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. Sleep. vol 45. issue 5. 2022-05-13. PMID:35554594. |
the diagnosis of narcolepsy type 1 (nt1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (csf) hypocretin-1/orexin-a level ≤ 110 pg/ml. |
2022-05-13 |
2023-08-13 |
Not clear |
| Marco Veneruso, Fabio Pizza, Elena Finotti, Giulia Amore, Stefano Vandi, Marco Filardi, Elena Antelmi, Lino Nobili, Alessandra Cassio, Andrea Pession, Giuseppe Plazz. Child Neurology: A Case Series of Heterogeneous Neuropsychiatric Symptoms and Outcome in Very Early-Onset Narcolepsy Type 1. Neurology. 2022-04-07. PMID:35387850. |
narcolepsy type 1 is a central disorder of hypersomnolence characterized by excessive daytime sleepiness, cataplexy (i.e., sudden loss of muscle tone during wakefulness triggered by emotions), and rapid eye movement sleep-related manifestations that can present with a peculiar phenotype when arising at a pediatric age. |
2022-04-07 |
2023-08-13 |
Not clear |
| Pablo Medrano-Martínez, Ángela Gómez-Sacristan, Rosa Peraita-Adrado. Is memory impaired in narcolepsy type 1? Journal of sleep research. 2022-04-07. PMID:35388527. |
memory deficits in narcolepsy with cataplexy type 1 (nt1) have been poorly studied, and the results are controversial. |
2022-04-07 |
2023-08-13 |
human |
| Adrienne Elisabeth van der Hoeven, Rolf Fronczek, Mink Sebastian Schinkelshoek, Frederik Willem Cornelis Roelandse, Jaap Adriaan Bakker, Sebastiaan Overeem, Denise Bijlenga, Gert Jan Lammer. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. Sleep. 2022-03-07. PMID:35255144. |
the diagnosis of narcolepsy type 1 (nt1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (csf) hypocretin-1/orexin-a level ≤110 pg/ml. |
2022-03-07 |
2023-08-13 |
Not clear |
| Emily Shelkowitz, Marie G Gantz, Ty A Ridenour, Ann O Scheimann, Theresa Strong, Jessica Bohonowych, Jessica Dui. Neuropsychiatric features of Prader-Willi syndrome. American journal of medical genetics. Part A. 2022-01-31. PMID:35098642. |
prader-willi syndrome (pws) is a genetic disorder characterized by hypotonia and poor feeding in infancy which progresses to hyperphagia in early-mid childhood, as well as developmental delays, a spectrum of behavioral and psychiatric concerns, endocrinopathies, orthopedic issues, and less commonly, seizures, sleep apnea, and narcolepsy with or without cataplexy. |
2022-01-31 |
2023-08-13 |
Not clear |
| Laura H Jacobson, Daniel Hoyer, Luis de Lece. Hypocretins (orexins): The ultimate translational neuropeptides. Journal of internal medicine. 2022-01-19. PMID:35043499. |
hcrt cell loss in humans leads to narcolepsy with cataplexy (narcolepsy type 1), a disorder characterized by intrusions of sleep into wakefulness, demonstrating that the hcrt system is nonredundant and essential for sleep/wake stability. |
2022-01-19 |
2023-08-13 |
Not clear |
| Vortioxetine Effects on Sleep Architecture in Treatment of Comorbid Depression in Adolescent Patient with Narcolepsy and Cataplexy: Case Report. Neuro endocrinology letters. vol 42. issue 8. 2021-12-30. PMID:34969190. |
vortioxetine effects on sleep architecture in treatment of comorbid depression in adolescent patient with narcolepsy and cataplexy: case report. |
2021-12-30 |
2023-08-13 |
Not clear |